BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $159,395 | $163,353 | $145,534 | $131,534 |
| % Growth | -2.4% | 12.2% | 10.6% | – |
| Cost of Goods Sold | $2,522 | $2,798 | $4,568 | $6,131 |
| Gross Profit | $156,873 | $160,555 | $140,966 | $125,403 |
| % Margin | 98.4% | 98.3% | 96.9% | 95.3% |
| R&D Expenses | $44,268 | $43,386 | $37,270 | $49,441 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $83,014 | $87,383 | $82,469 | $80,470 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $127,282 | $130,769 | $119,739 | $129,911 |
| Operating Income | $29,591 | $29,786 | $21,227 | -$4,508 |
| % Margin | 18.6% | 18.2% | 14.6% | -3.4% |
| Other Income/Exp. Net | -$17,461 | -$23,300 | -$20,469 | -$21,483 |
| Pre-Tax Income | $12,130 | $6,486 | $758 | -$25,991 |
| Tax Expense | -$769 | $1,401 | $726 | $804 |
| Net Income | $12,899 | $5,085 | $32 | -$26,795 |
| % Margin | 8.1% | 3.1% | 0% | -20.4% |
| EPS | 0.061 | 0.02 | 0 | -0.13 |
| % Growth | 207% | – | 100% | – |
| EPS Diluted | 0.059 | 0.02 | 0 | -0.13 |
| Weighted Avg Shares Out | 210,176 | 209,519 | 208,882 | 207,381 |
| Weighted Avg Shares Out Dil | 219,885 | 219,886 | 215,261 | 207,381 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,238 | $2,516 | $3,024 | $3,570 |
| Interest Expense | $19,661 | $21,582 | $23,494 | $24,449 |
| Depreciation & Amortization | $335 | $329 | $331 | $309 |
| EBITDA | $32,126 | $28,397 | $24,583 | -$1,233 |
| % Margin | 20.2% | 17.4% | 16.9% | -0.9% |